Zealand Pharma
Zealand Pharma
Explore linked clinical trials.11 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-07 | NCT07843498 | |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, nutritional disorder, obesity disorder, overnutrition, type 2 diabetes mellitus | Recruiting | Phase 3 | 2026-10-07 | NCT07843485 | |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-10-07 | NCT07843472 | |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS | Digestive System Diseases, Intestinal Failure, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, digestive system disorder, disease, intestinal disorder, malabsorption syndrome, metabolic disease, short bowel syndrome, syndromic disease | Recruiting | Phase 3 | 2026-09-29 | NCT07197944 | |
| A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 2 | 2026-09-09 | NCT07589686 | |
| A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Early phase 1 | 2026-08-13 | NCT07721597 | |
| Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome | Digestive System Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, digestive system disorder, intestinal disorder, malabsorption syndrome, metabolic disease, short bowel syndrome | Active, not recruiting | Phase 3 | 2026-07-30 | NCT07228403 | |
| A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period | Plaque Psoriasis | Recruiting | Phase 1 | 2026-07-29 | NCT07733089 | |
| Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function | Impaired Hepatic Function | Recruiting | Phase 1 | 2026-07-06 | NCT07682818 | |
| A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants | Healthy Volunteers | Recruiting | Phase 1 | 2026-02-17 | NCT06682975 | |
| Dapiglutide for the Treatment of Obesity | Body Weight, Inflammation, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 2 | 2024-12-05 | NCT05788601 |